Publications by authors named "Elena Tomas-Guillen"
Article Synopsis
- The study analyzed 10 years of data on adult patients with solid tumors enrolled in clinical trials, focusing on the clinical characteristics and the financial impact of sponsor contributions to drug costs.
- Over the decade, the number of clinical trials increased significantly from 140 in 2010 to 459 in 2019, with a shift in drug use from mainly targeted therapies to a greater emphasis on immunotherapy.
- The analysis showed that while the overall expenditure on antineoplastic drugs outside clinical trials was over EUR 120 million, sponsor contributions in trial settings amounted to about EUR 107 million, resulting in a potential cost avoidance of around EUR 92 million.
Background: Cancer is one of the leading causes of morbidity and mortality in the world. Its growing incidence and prevalence, as well as the advances in diagnostic and treatment tools, motivate an open debate about the economic burden it may place on health systems and have raised concerns about access to this technological innovation. There is a lack of information on the detailed costs of pharmacological treatment of cancer in our health setting.
View Article and Find Full Text PDF